Pharma firm to list on NSE SME platform on August 18; proceeds to support plant upgrades, working capital, and corporate purposes
Medistep Healthcare will launch its Initial Public Offer (IPO) on Friday, August 8, 2025. The offer will remain open for subscription until Tuesday, August 12, 2025. The equity shares are scheduled to be listed on the NSE SME platform on Monday, August 18, 2025.
Fast Track Finsec is acting as the Lead Manager for the issue, while Cameo Corporate Services Limited is serving as the Registrar.
The company, which engages in the manufacturing of sanitary pads and energy powder, and trades in pharmaceutical, nutraceutical, surgical, and intimate products, has fixed the issue price at ₹43 per equity share. The IPO aims to raise ₹16.09 crore.
According to the company, the proceeds from the IPO will be used for capital expenditure towards the purchase of plant and machinery for expanding its current manufacturing facility, meeting working capital requirements, and fulfilling general corporate purposes.
A total of 37,44,000 equity shares of face value ₹10 each are being offered. The minimum investment lot is 3,000 equity shares. Of the total, 17.79 lakh equity shares are reserved for retail investors, 17.76 lakh equity shares for non-institutional investors, and 1.89 lakh equity shares for market makers.
Girdhari Lal Prajapati, Managing Director, Medistep Healthcare, said, “The proceeds from the IPO will strategically support our expansion efforts and reinforce our footprint in both domestic and international markets. Our diversified and growing product portfolio—including sanitary pads, energy powders, pharmaceuticals, nutraceuticals, surgical supplies, and intimate care products—positions us well to capitalise on the rising global & domestic demand for health and hygiene solutions. With increasing consumer awareness and a rapidly evolving pharmaceutical market, we are confident in our ability to scale operations, drive market penetration, and deliver sustained value to our stakeholders.”
Founded in 2023, the company has established a distribution network and offers low-cost products through retail and distributor channels. Medistep Healthcare recorded revenue from operations of ₹4,965.48 lakh in FY25, up from ₹3,907.19 lakh in FY24. Its EBITDA grew from ₹454.2 lakh in FY24 to ₹560 lakh in FY25, while profit after tax rose from ₹332.76 lakh to ₹414.42 lakh over the same period.
Following the listing, the company’s market capitalisation will stand at ₹61.10 crore.
